Medicine is advancing in great strides: 25 new drugs have already been approved by the FDA in 2026.
The latest addition is Merck's Enlicitide, the world's first oral PCSK9 inhibitor for lowering LDL cholesterol.
Together with Eli Lilly's oral GLP-1 drug Orforglipron and new treatments for conditions including high blood pressure and diabetes, this year's approvals illustrate a clear trend:
We are becoming increasingly good at preventing disease, not just treating it.
At Executive Health, we strongly believe in this important paradigm shift. Early diagnostics and lifestyle changes will remain the foundation, but a growing number of effective medicines also gives us the opportunity to reduce the risk of the diseases that affect our health and longevity the most.
